219 related articles for article (PubMed ID: 26513697)
1. Vemurafenib-induced pityriasis amiantacea: a case report.
Bilgiç Ö
Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
10. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
Boudewijns S; Gerritsen WR; Koornstra RH
BMC Cancer; 2014 Dec; 14():967. PubMed ID: 25515496
[TBL] [Abstract][Full Text] [Related]
11. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.
Yamazaki N; Kiyohara Y; Sugaya N; Uhara H
J Dermatol; 2015 Jul; 42(7):661-6. PubMed ID: 25884515
[TBL] [Abstract][Full Text] [Related]
13. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
14. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
15. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
16. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.
Wolf SE; Meenken C; Moll AC; Haanen JB; van der Heijden MS
BMC Cancer; 2013 Dec; 13():561. PubMed ID: 24289205
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease.
Brugière C; Stefan A; Morice C; Cornet E; Moreau A; Allouche S; Verneuil L
Br J Dermatol; 2014 Dec; 171(6):1529-32. PubMed ID: 25066094
[TBL] [Abstract][Full Text] [Related]
18. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
[No Abstract] [Full Text] [Related]
19. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Chon SY; Sambrano BL; Geddes ER
J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib and cutaneous adverse events--report of five cases.
Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]